Today’s pharmaceutical industry faces unprecedented challenges. Among these broad challenges are the genericization of blockbuster brands, declining R&D productivity, and a challenging payer environment. Pharmaceutical companies have traditionally generated value through R&D. However, the decline in R&D productivity has forced companies to question the long-term sustainability of their own R&D. Our research shows that stagnant R&D productivity is a key cause of the problems faced by the industry, a view echoed by pharma executives. Evidence shows that the current output from R&D activities is insufficient to grow future sales. The purpose of this report is to explore the key challenges facing pharma companies and include case studies to provide context on the industry’s challenges.
Questions Answered:
• What evidence is there to suggest that R&D productivity is a central cause of the challenges confronting pharma companies today?
• How does a challenging payer environment exacerbate the R&D productivity issues facing pharma companies?
• What factors will affect how much the “patent cliff” will impact on a company’s sales?
• How has healthcare reform in the United States and austerity measures in Europe impacted on pharmaceutical sales for leading pharma companies?
Report Contents:
INTRODUCTION
THE CHALLENGES
PATENT EXPIRY OF BLOCKBUSTER BRANDS
DECLINING R&D PRODUCTIVITY
INCREASING COST TO DEVELOP PHARMACEUTICALS
Morbidity and Mortality Evidence Potentially Increases Development Costs
PAYER ENVIRONMENT
Healthcare Reform in the United States
Pricing Pressures in Europe Due to Austerity Measures
Scrutiny from Payers on the Cost-Effectiveness of Pharmaceuticals
R&D PRODUCTIVITY IS CENTRAL TO THE CHALLENGES FACING THE INDUSTRY
CONCLUSION
To order a copy of the report or for further information, please visit us at https://wescadiagroup.com/
About Wescadia Group
Wescadia Group is a healthcare consultancy firm that works with life science organizations to help them achieve sustainable growth, bring innovative treatments to market and maximize the value of their assets.
Contact:
Wescadia Group Pty Ltd (ABN 26.156.459.504)
Marcus Bain
Managing Director
Phone: +61. 8.8125.5820
Email: marcus.bain@
Website: http://wescadiagroup.com/
Facebook: http://www.facebook.com/
Linkedin: http://www.linkedin.com/
Twitter: https://twitter.com/
